Otonomy/ US68906L1052 /
22/12/2022 21:59:49 | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.09USD | - | 196,134 Turnover: 17,122.85 |
-Bid Size: - | -Ask Size: - | 0.09 | 0.08 |
GlobeNewswire
08/08
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of...
GlobeNewswire
28/02/2022
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire
22/02/2022
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
GlobeNewswire
17/02/2022
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
GlobeNewswire
16/02/2022
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
GlobeNewswire
14/02/2022
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021
GlobeNewswire
08/02/2022
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans ...
GlobeNewswire
07/02/2022
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
GlobeNewswire
25/01/2022
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meetin...
GlobeNewswire
11/01/2022
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis ...
GlobeNewswire
06/12/2021
AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors
GlobeNewswire
16/11/2021
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
GlobeNewswire
12/11/2021
AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalm...
GlobeNewswire
10/11/2021
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update